Liotta and Petricoin to Discuss Personalized Medicine in Vision Series Lecture
Posted: April 21, 2008 at 1:00 am, Last Updated: November 30, -0001 at 12:00 am
Lance Liotta and Emanuel Petricoin, co-directors of the Center for Applied Proteomics and Molecular Medicine, will present “The Dawn of the Age of Personalized Therapy: Proteomic Technologies and Strategies for Implementation” at the next Vision Series on Monday, April 21, at 8 p.m.
The lecture will take place on Mason’s Fairfax Campus in the Center for the Arts Concert Hall. Admission is free, but tickets are required. Reserve tickets online, at the Center for the Arts ticket office, Tuesday through Saturday, 10 a.m. to 6 p.m., or the evening of the presentation.
A reception will follow the lecture.
The field of molecular medicine is moving beyond genomics to proteomics and a systems biology approach to disease.
While DNA is the information archive, proteins do all the work of the cell and ultimately dictate all biological processes. It is the proteins themselves that are most often the drug targets, especially in the new era of personalized therapy where cellular “circuitry” is being targeted.
These pathways consist of protein networks, not genes, and these networks are controlled by processes that cannot be predicted by genetic analysis. The future of patient-tailored therapy will rely on new proteomic approaches to discover and profile cellular “circuitry” within a tiny biopsy specimen.
Liotta and Petricoin have developed a cadre of new technologies and approaches to translational medicine whereby ex-vivo molecular targeting takes place as an entrée into patient selection and personalization of therapy.
Liotta was formerly chief of the Laboratory of Pathology at the National Cancer Institute’s Center for Cancer Research for more than 20 years and chief of the center’s Tumor Invasion and Metastases section.
He also chaired the National Institutes of Health Radiation Safety Committee. He earned his medical degree from Case Western Reserve Medical School and is licensed to practice medicine in Maryland. Liotta also holds a doctoral degree in biomedical engineering from Case Western Reserve University.
Before joining Mason, Petricoin was with the U.S. Food and Drug Administration. He had a three-year postgraduate fellowship with the agency, then became senior investigator in the Office of Cell Tissue and Gene Therapies in the Center for Biologics Evaluation and Research. Petricoin holds a doctorate in microbiology from the University of Maryland at College Park.